Sanford Burnham
  • Sanford Burnham
  • Twitter
  • Facebook
  • Youtube
  • Navigate Sanford-Burnham
    • Main Site
    • Our Mission
    • Research
    • Talent
    • Technology
    • Training & Education
    • Our Supporters
    • News

Beaker

Sanford-Burnham Science Blog

Subscribe

Personalized medicine event in San Diego

by Kristina Meek on March 29, 2013 at 5:57 am | 0 Comments
Full Article
Michael Jackson, Ph.D., vice president of drug discovery and development in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (photo by Mark Dastrup)

Michael Jackson, Ph.D., vice president of drug discovery and development in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (photo by Mark Dastrup)

On April 4, the San Diego chapter of Oxbridge Biotech Roundtable (OBR) will present a free event, Personalized Medicine: Road to New Opportunities.

Drug development scientist Rita Lim-Wilby, Ph.D. will lead a panel discussion on this fascinating and quickly evolving topic. The panel includes Michael Jackson, Ph.D., Sanford-Burnham’s vice president of drug discovery and development, Rob Bookstein, M.D., of Illumina, James Christensen, Ph.D., of Pfizer, Ashley Van Zeeland, Ph.D., M.B.A., of Cyber Genomics, and Paul Billings, M.D., Ph.D., of Life Technologies.

What: Personalized Medicine: Road to New Opportunities
When: Thursday, April 4, 2013, 5:15 p.m. PT
Where: W.M. Keck Foundation Amphitheater, The Scripps Research Institute
10550 N. Torrey Pines Rd, La Jolla, CA 92037
Registration: http://www.oxbridgebiotech.com/events/personalizedmedicine

Read More

Collaborating with Mayo Clinic to speed drug discovery

by Heather Buschman, Ph.D. on March 11, 2013 at 7:00 am | 1 comment
Full Article
Michael Jackson, Ph.D., vice president of drug discovery and development in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (photo by Mark Dastrup)

Michael Jackson, Ph.D., vice president of drug discovery and development in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (photo by Mark Dastrup)

We announced today that we’ve signed a new collaborative agreement with Mayo Clinic to build a pipeline of therapeutic drugs aimed at a variety of diseases with serious unmet medical needs. Under this agreement, Mayo Clinic scientists will work with researchers in our Conrad Prebys Center for Chemical Genomics (Prebys Center) to conduct early-stage drug discovery, including assay development, high-throughput screening, and lead identification.

Read More

Disease in a dish: the ultimate personalized medicine

by Heather Buschman, Ph.D. on December 7, 2012 at 5:15 am | 0 Comments
Full Article
DTW

The latest episode of Developments to Watch, our collaborative video series produced by Medscape, is now available online: Disease in a Dish: The Ultimate Personalized Medicine.

In the video, Sanford-Burnham CEO John Reed, M.D., Ph.D., talks to Michael Jackson, Ph.D., vice president of drug discovery and development, about the Institute’s work on creating personalized “disease in a dish” models using stem cells derived from patients. They also talk about drug repurposing—finding new applications for existing therapeutic drugs in order to get treatments to patients faster.

Here’s an excerpt:

Read More

The Atlantic Meets Sanford-Burnham

by Kristina Meek on November 1, 2011 at 2:15 pm | 0 Comments
Full Article
The Atlantic Meets the Pacific lab experience

A group from The Atlantic Meets the Pacific conference tours the Stem Cell Research Center at Sanford-Burnham's San Diego campus. (Photo by Mark Dastrup)

When The Atlantic magazine was looking for a location to host its first West Coast symposium, the Torrey Pines Mesa area of San Diego sprang to their attention. As Atlantic Vice President Elizabeth Baker Keffer wrote in her welcome, “The research hub of San Diego makes this the perfect location to experience the interdisciplinary experiments occurring on the front line of discovery.” They partnered with UC San Diego to present The Atlantic Meets the Pacific, October 17-19.

Sanford-Burnham joined The Scripps Research Institute, the Salk Institute, Scripps Institution of Oceanography, and UC San Diego’s Calit2 and Moores Cancer Center in representing the powerhouse of scientific ideas that resides here overlooking the Pacific Ocean.

Read More

Discovering the future

by Josh Baxt on June 9, 2011 at 7:56 am | 0 Comments
Full Article
Dr. Anthony Tether, Dr. Michael Jackson, Duane Roth and Greg Lucier

Dr. Anthony Tether, Dr. Michael Jackson, Duane Roth and Greg Lucier

What will the future look like? On June 5, four research experts and around 200 guests gathered at the Hilton La Jolla Torrey Pines to answer this question. The event, Sanford-Burnham’s annual President’s Circle reception, brought together Dr. Anthony Tether, former director of  the Defense Advanced Research Projects Agency (DARPA), Greg Lucier, chairman of both Life Technologies and the Sanford-Burnham board of trustees and Dr. Michael Jackson, vice president of Drug Discovery at Sanford-Burnham and was moderated by Duane Roth, CEO of CONNECT. Together, they shared their thoughts on how research will impact human health in coming years.

DARPA has been a key part of the United States’ technological success for 50 years. The agency was created after the first Sputnik launch, an event that shocked the American public and led to new approaches to research. “DARPA was initiated to create technological surprise,” said Dr. Tether.

Read More

Visiting With a Good Friend

by Josh Baxt on February 10, 2011 at 1:20 pm | 1 comment
Full Article

You might have thought Conrad Prebys had been given 50 yard-line seats to the Super Bowl—that’s how thrilled he was to visit Sanford-Burnham. Two years ago, Prebys made a $10 million gift to support chemical genomics at the Institute. He stopped by on February 10 to learn how the research at the Conrad Prebys Center for Chemical Genomics is progressing and to tour one of our labs.

First the tour. Dr. Hudson Freeze studies congenital disorders of glycosolation (CDG), a family of rare diseases in which defective enzymes fail to add necessary sugar chains to proteins, creating multiple medical issues. CDG is fatal in 20 percent of affected children. While visiting the Freeze lab, Prebys met several researchers and spoke via Skype with a CDG patient, a young woman in the Netherlands who has spent a significant portion of her life in hospitals. Researchers in the Freeze lab are looking for creative ways to fix the enzyme deficiencies that cause these conditions.

Read More

New Partnership Targets Brain Conditions

by Josh Baxt on January 18, 2011 at 9:27 am | 1 comment
Full Article
Robots in the Prebys Center screen hundreds of thousands of compounds to find the handful that could become new medicines.

Robots in the Prebys Center screen hundreds of thousands of compounds to find the handful that could become new medicines.

Sanford-Burnham has been conducting cutting-edge research on neurological and neuropsychiatric conditions for many years and recently that research received a big boost. The Institute announced a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., (OMJPI), a division of Johnson & Johnson, to discover new drugs to treat Alzheimer’s diseaseand major psychiatric disorders.Under the agreement, Sanford-Burnham will look for new therapeutic targets for Alzheimer’s disease and neuropsychiatric conditions. Then, the Conrad Prebys Center for Chemical Genomics (Prebys Center) will identify chemical compounds that therapeutically alter those targets. These compounds will then be optimized and directed into OMJPI’s drug pipeline.

 

Read More

What is “Disease in a Dish?”

by Heather Buschman, Ph.D. on January 12, 2011 at 11:34 am | 6 Comments
Full Article
"Disease in a dish" has great potential to accelerate drug discovery.

"Disease in a dish" has great potential to accelerate drug discovery.

“Disease in a dish” is a cutting-edge, stem cell-based strategy that allows researchers to study an individual patient’s cells in a laboratory dish. Traditionally, scientists interested in a particular disease have used a standard cell line that has been grown in the lab for years or a mouse model (if one exists) that has been engineered to mimic the disease. Although extremely valuable, these techniques have obvious limitations. Animal models never entirely reflect the actual human condition – they don’t capture the complicated interplay between an individual patient’s genetics and the environmental factors that might influence the development of the disease or that patient’s response to a new therapy.

Read below to find out how diseases in a dish are made, how they’re being used to study and treat disease and how Sanford-Burnham researchers are applying the technique.

Read More

Sanford-Burnham Robots on TV

by Heather Buschman, Ph.D. on September 16, 2010 at 2:03 pm | 0 Comments
Full Article

The hard-working robots and scientists in Sanford-Burnham’s Conrad Prebys Center for Chemical Genomics (Prebys Center) were profiled in three local news spots in the past week: Fox 35 Orlando, ABC 6 Orlando and NBC 7 San Diego (in collaboration with Voice of San Diego).

Read More

Sanford-Burnham at BIO

by Josh Baxt on May 21, 2010 at 2:25 pm | 1 comment
Full Article

Biotech industry representatives from around the world met at the 2010 BIO International Conventionin Chicago in early May to learn about new research and discuss industry trends. The event drew 15,322 industry leaders from 49 states and 65 countries.Amidst a sea of state and country banners hung throughout the immense exhibition hall, Sanford-Burnham had a presence in both the California and Florida pavilions. Chief Business Officer Dr. Paul Laikind and Vice President for Drug Discovery and Development Dr. Michael Jackson spoke with potential partners about moving Sanford-Burnham technology closer to patients.

Read More

Partners, part 2

by Josh Baxt on April 7, 2010 at 12:21 pm | 3 Comments
Full Article
Partners

The high-throughput robots at the Prebys Center screen for chemical compounds that beneficially alter protein function.

Michael Jackson, Ph.D., knows drug discovery. Dr. Jackson spent 15 years with Johnson & Johnson in a number of positions, including Senior Vice President of Drug Discovery at Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), where he established their state-of-the-art drug discovery site in San Diego. Under his leadership, J&J PRD delivered numerous drug candidates into preclinical development, many of which went on to clinical trials.Dr. Jackson recently joined Sanford-Burnham as Vice President for Drug Discovery and Development. In this role, Dr. Jackson leads Sanford-Burnham’s efforts to identify drug candidates, develop promising chemical compounds into new medicines and create partnerships for preclinical and clinical drug development. In essence, his job is to take the basic science discoveries at Sanford-Burnham and help translate them into new medicines.

Read More

Search

Find more information

  • About Beaker
  • Contact us
  • Donate

Please take a quick survey

Which of these items describes you?

Select all that apply. (Question 1 of 5)

Categories

  • Basic Research
  • Cancer
    • Apoptosis & Cell Death Research
    • Signal Transduction
    • Tumor Development
    • Tumor Microenvironment
  • Children's Health
    • Genetic Diseases
    • Muscle Development & Regeneration
    • RNA Biology
  • Diabetes & Obesity
    • Cardiovascular Pathobiology
    • Metabolic Signaling & Disease
  • Drug Discovery
  • Events
  • Graduate School of Biomedical Sciences
  • Grants
  • Infectious & Inflammatory Diseases
    • Bioinformatics & Systems Biology
    • Infectious Diseases
    • Inflammatory Diseases
  • Nanomedicine
  • Neuroscience, Aging, & Stem Cells
    • Degenerative Diseases
    • Development & Aging
    • Stem Cells
  • Other
  • People
  • Sanford-Burnham Supporters
  • Translational Medicine

Search by Keyword

Alzheimer's disease CCRA CIRM collaboration commitment communication community Conrad Prebys Center for Chemical Genomics Daniel Kelly Erkki Ruoslahti Evan Snyder Florida Hospital Fred Levine Genetic Disease Program Guy Salvesen Hudson Freeze John Reed Kristiina Vuori La Jolla Lake Nona Metabolic Signaling metabolism NIH Orlando personalized medicine Prebys Center press proteins Rare Diseases Rare disease symposium research publications Robert Wechsler-Reya Santa Barbara Sara Courtneidge Stem Cells Steven Smith Stuart Lipton T. Denny Sanford technology Translational Research Institute tumor microenvironment Tumor Microenvironment Program Video Yu Yamaguchi Ze'ev Ronai

© Sanford-Burnham Medical Research Institute. All rights reserved.

Get Cloud PHP Hosting on CatN